ES2139553T1 - REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION. - Google Patents

REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION.

Info

Publication number
ES2139553T1
ES2139553T1 ES97921094T ES97921094T ES2139553T1 ES 2139553 T1 ES2139553 T1 ES 2139553T1 ES 97921094 T ES97921094 T ES 97921094T ES 97921094 T ES97921094 T ES 97921094T ES 2139553 T1 ES2139553 T1 ES 2139553T1
Authority
ES
Spain
Prior art keywords
replication
cultivation
mammalian cells
influenza viruses
vaccine production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES97921094T
Other languages
Spanish (es)
Inventor
Robert G Webster
Nicolai V Kaverin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Jude Childrens Research Hospital
Original Assignee
St Jude Childrens Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Research Hospital filed Critical St Jude Childrens Research Hospital
Publication of ES2139553T1 publication Critical patent/ES2139553T1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION PROPORCIONA LA REPLICACION DE LAS CEPAS DE MAS FUERTE CRECIMIENTO DEL VIRUS DE LA GRIPE, DERIVADAS DE AISLADOS CLINICOS, EN CELULAS CULTIVADAS DE MAMIFEROS, POR INFECCION DE LAS CELULAS DE MAMIFEROS CON LAS CEPAS DE FUERTE CRECIMIENTO, A FIN DE OBTENER CELULAS INFECTADAS, Y POR CULTIVO DE LAS CELULAS MIENTRAS SE MANTIENE EN EL MEDIO DE CULTIVO UN MARGEN DE CONCENTRACION DE TRIPSINA DE 0,05 A 1,0 MI G/ML, DONDE EL VIRUS REPLICADO RESULTANTE ES ADECUADO PARA SU USO EN VACUNAS CONTRA LA GRIPE DE LOS MAMIFEROS, ASI COMO PROCEDIMIENTOS DE VACUNACION QUE PROPORCIONA IGUALMENTE LA INVENCION.THE INVENTION PROVIDES THE REPLICATION OF THE STRONGEST STRAINS OF THE INFLUENZA OF THE FLU, DERIVED FROM CLINICAL ISOLATES, IN CULTIVATED CELLS OF MAMMALS, BY INFECTION OF THE CELLS OF MAMMALS, FINALLY GROWED, TO AND PER CULTURE OF THE CELLS WHILE A TRIPSINE CONCENTRATION MARGIN OF 0.05 TO 1.0 MY G / ML IS MAINTAINED IN THE CULTURE, WHERE THE RESULTING REPLICATED VIRUS IS SUITABLE FOR USE IN VACCINES AGAINST THE MAMMALS, AS WELL AS VACCINATION PROCEDURES ALSO PROVIDED BY THE INVENTION.

ES97921094T 1996-04-05 1997-04-02 REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION. Pending ES2139553T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62838496A 1996-04-05 1996-04-05
US08/664,783 US5824536A (en) 1994-08-23 1996-06-17 Influenza virus replicated in mammalian cell culture and vaccine production

Publications (1)

Publication Number Publication Date
ES2139553T1 true ES2139553T1 (en) 2000-02-16

Family

ID=27090697

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97921094T Pending ES2139553T1 (en) 1996-04-05 1997-04-02 REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION.

Country Status (8)

Country Link
US (2) US5824536A (en)
EP (1) EP0895535A4 (en)
AU (1) AU2722997A (en)
CA (1) CA2250716A1 (en)
DE (1) DE895535T1 (en)
ES (1) ES2139553T1 (en)
NO (1) NO984565L (en)
WO (1) WO1997038094A1 (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612967A1 (en) * 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process
NZ512980A (en) * 1998-12-17 2003-07-25 Aventis Pasteur Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
IL136232A0 (en) * 2000-05-18 2001-05-20 Bar Ilan University Res Author Measurements of enzymatic activity in a single, individual cell in population
DE10144906B4 (en) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Process for the large-scale production of vaccines
WO2003035824A1 (en) * 2001-10-25 2003-05-01 Bar-Ilan University Interactive transparent individual cells biochip processor
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6830917B2 (en) 2001-12-10 2004-12-14 Baxter Healthcare S.A. Method of isolation and purification of trypsin from pronase protease and use thereof
WO2003076462A1 (en) * 2002-03-08 2003-09-18 Crucell Holland B.V. Use of recombinant trypsin for vaccine production
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN1678345A (en) 2002-04-26 2005-10-05 米迪缪尼疫苗股份有限公司 Multiplasmid System for Preparation of Influenza Virus
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
CA2807534A1 (en) 2003-02-25 2005-02-17 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
IL154677A0 (en) * 2003-02-27 2003-09-17 Univ Bar Ilan A method and apparatus for manipulating an individual cell
WO2004110484A1 (en) * 2003-06-18 2004-12-23 Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' Method for producing a live tissue-cultural vaccine against influenza virus
RU2330885C2 (en) * 2003-06-18 2008-08-10 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУ ГНЦ ВБ "Вектор" Роспотребнадзора) Method of production of live culture influenza virus vaccines
CA2503774C (en) * 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
EP1654347B1 (en) * 2003-06-26 2014-06-04 Seng Enterprises Limited Improved materials for constructing cell-chips, cell-chip covers, cell-chip coats, processed cell-chips and uses thereof
US8597597B2 (en) * 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7888110B2 (en) * 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
US7982751B2 (en) * 2003-07-11 2011-07-19 The University Of North Carolina Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
ATE469972T1 (en) * 2003-12-23 2010-06-15 Medimmune Llc MULTIPLASMID SYSTEM FOR GENERATING THE FLU VIRUS
EP1711166A1 (en) * 2004-02-03 2006-10-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
US7403647B2 (en) * 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
EP1763665A1 (en) * 2004-07-07 2007-03-21 Seng Enterprises Limited Method and device for identifying an image of a well in an image of a well-bearing component
WO2006021959A2 (en) * 2004-08-25 2006-03-02 Seng Enterprises Ltd. Method and device for isolating cells
PL2236155T3 (en) * 2004-09-09 2012-10-31 Novartis Ag Decreasing potential iatrogenic risks associated with influenza vaccines
FR2878860A1 (en) * 2004-12-08 2006-06-09 Vivalis Sa HUMAN STEM CELL LINES DERIVED FROM ES CELLS AND USES FOR THE PRODUCTION OF RECOMBINANT VACCINES AND PROTEINS
CN103555670B (en) * 2004-12-23 2015-08-12 米迪缪尼有限公司 For the non tumorigenic MDCK cell system of virus multiplication
ES2352344T3 (en) 2005-01-25 2011-02-17 Seng Enterprises Limited MICROFLUID DEVICE FOR CELL STUDY.
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
CA2613283A1 (en) * 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
DE102005034043B4 (en) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Mixture containing L-carnitine and trehalulose and product containing the mixture
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
US20070141555A1 (en) * 2005-10-11 2007-06-21 Mordechai Deutsch Current damper for the study of cells
ES2359214T5 (en) * 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Viral vaccines derived from cells with reduced levels of residual cellular DNA by treatment with beta-propiolactone
WO2007052245A1 (en) * 2005-11-03 2007-05-10 Seng Enterprises Ltd. Method and device for studying floating, living cells
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL1945252T3 (en) 2005-11-04 2013-11-29 Seqirus Uk Ltd Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
BRPI0618254A2 (en) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic free aqueous phase surfactant emulsions to provide adjuvant to split influenza vaccines
JP5491173B2 (en) 2006-04-19 2014-05-14 メディミューン，エルエルシー Methods and compositions for expressing minus-strand viral RNA in canine cells
WO2008032219A2 (en) * 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
EP2069480B1 (en) * 2006-09-15 2014-03-19 MedImmune, LLC Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
US20080102505A1 (en) * 2006-09-18 2008-05-01 Petrie Thomas R Jr Method of treating viral infections with ultraviolet light
EP1911836A1 (en) 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Medium supplement for virus production
US20110053248A1 (en) * 2006-10-23 2011-03-03 Medimmune, Llc Serum-Free Virus Propagation Platform For A Virus Vaccine Candidate
CN101553252A (en) * 2006-12-06 2009-10-07 诺华有限公司 Vaccine comprising antigens from four strains of influenza virus
EP2091561A2 (en) * 2006-12-15 2009-08-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
CN101610787B (en) * 2006-12-15 2013-07-03 先灵-普劳有限公司 Method for replicating influenza virus in culture
EP2139908A4 (en) * 2007-03-12 2011-02-16 Antigen Express Inc Li-rnai involved li suppression in cancer immunotherapy
JP2010523724A (en) * 2007-04-13 2010-07-15 アカデミア シニカ α-Galactosylceramide analogues and their use as immunotherapeutic agents
US7758867B2 (en) * 2007-06-15 2010-07-20 Biotrion Co., Ltd. Attenuated influenza virus and a live vaccine comprising the same
EP2069484B1 (en) 2007-06-18 2014-08-13 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide
US9145540B1 (en) 2007-11-15 2015-09-29 Seng Enterprises Ltd. Device for the study of living cells
US9975118B2 (en) 2007-11-15 2018-05-22 Seng Enterprises Ltd. Device for the study of living cells
RU2377295C1 (en) * 2008-06-11 2009-12-27 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Nutrient medium for mammal cell cultivation
US7928077B2 (en) * 2008-07-11 2011-04-19 Academia Sinica Alpha-galactosyl ceramide analogs and their use as immunotherapies
RU2011107757A (en) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) INFLUENZA VACCINES
CA2738024A1 (en) 2008-09-24 2010-04-01 Medimmune, Llc Methods for purification of viruses
BRPI0919252A2 (en) * 2008-09-24 2015-08-11 Medimmune Llc Methods for cell cultivation, virus propagation and purification
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2427547A1 (en) * 2009-05-08 2012-03-14 GlaxoSmithKline Biologicals S.A. Method for producing virus from cell culture involving homogenization
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
BR112012000826B1 (en) 2009-07-06 2022-07-26 Variation Biotechnologies Inc METHOD FOR THE PREPARATION OF VESICLES
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
TW201202425A (en) 2010-04-28 2012-01-16 Abbott Biologicals Bv Production of viral components
BR112012028146A2 (en) * 2010-05-06 2015-09-15 Novartis Ag organic peroxide compounds for inactivation of microorganisms
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
EP2704740B1 (en) 2011-05-04 2016-10-05 Streck, Inc. Inactivated swine flu virus and methods of preparing it
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
CN104244984B (en) 2012-01-27 2020-03-31 变异生物技术公司 Methods and compositions for therapeutic agents
EP3740234A1 (en) 2018-01-18 2020-11-25 Yisheng Biopharma (Singapore) Pte. Ltd. Method for adapting influenza viruses to vero cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2445301A (en) * 1941-12-05 1948-07-13 Univ Pennsylvania Influenza vaccine
BE662899A (en) * 1964-04-22
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
EP0791055B1 (en) * 1994-11-10 2012-01-25 Baxter Healthcare S.A. Method for producing biologicals in protein-free culture
WO1996015232A1 (en) * 1994-11-16 1996-05-23 St. Jude Children's Research Hospital Novel replication process

Also Published As

Publication number Publication date
NO984565D0 (en) 1998-09-30
EP0895535A1 (en) 1999-02-10
EP0895535A4 (en) 2004-09-15
US5824536A (en) 1998-10-20
AU2722997A (en) 1997-10-29
WO1997038094A1 (en) 1997-10-16
US6344354B1 (en) 2002-02-05
CA2250716A1 (en) 1997-10-16
DE895535T1 (en) 2000-03-02
NO984565L (en) 1998-12-03

Similar Documents

Publication Publication Date Title
ES2139553T1 (en) REPLICATION OF INFLUENZA VIRUSES IN A CULTIVATION OF MAMMALIAN CELLS AND VACCINE PRODUCTION.
EP2011862B1 (en) Method for manufacturing an active component of a medicine or diagnosis agent in MDCK cell suspension culture
ES2129386T1 (en) INFLUENZA VACCINE.
Maassab et al. Laboratory and clinical characteristics of attenuated strains of influenza virus
MX9306841A (en) UREASE BASED VACCINE AGAINST HELICOBACTER INFECTION IN MAMMALS.
BRPI0407636A (en) cell culture medium, animal cell lineage, methods for producing a conditioned culture medium, animal cells, an animal cell culture, virus in an animal cell culture, or preferably anchor-dependent diploid human, method for produce a vaccine, and virus population
US4188375A (en) Process for the preparation of vaccines
EP1427817A1 (en) Multiplication of viruses in a cell culture
AR032575A1 (en) USE OF AN ANTIGEN FLU PREPARATION FOR THE MANUFACTURE OF AN INTRADERMIC VACCINE OF THE FLU AND PHARMACEUTICAL CASE THAT INCLUDES SUCH VACCINE
CO5540349A2 (en) VACCINAL PREPARATION OF INACTIVATED INFLUENZA VIRUS
ES2074968B1 (en) NEW STRAINED AERUGINOUS PSEUDOMONAS STRAINS.
MX9802285A (en) Parainfluenza virus glycoproteins and vaccines.
ES2038689T3 (en) PROCEDURE FOR THE CULTIVATION OF INFECTIOUS RHYTHNOTRACHEITIS PAVA VIRUSES AND A VACCINE PREPARED FROM VIRUSES SO OBTAINED.
AR053286A2 (en) CULTIVATION OF CELLS FROM A CEPA DERIVED FROM A SPEC PROGENITRA OF A SPECIES OF NEOSPORA, VACCINE THAT CONTAINS THEM, METHODS TO PREPARE SUCH CULTURE, METHOD TO PREPARE A VACCINE WITH SUCH CULTURE, METHOD TO VACCINE A VACCINE THAT DATES CELLS
ES2106784T3 (en) TRANSFER FACTOR AND METHODS OF USE.
PE20211648A1 (en) COMPOSITION OF COMBINED VACCINE INCLUDING REDUCED DOSES OF INACTIVATED POLIO VIRUS AND METHOD OF PREPARING IT
PE72699A1 (en) ROTAVIRUS ANTIGEN, VACCINE AND DIAGNOSTIC AGENT FOR ROTAVIRUS INFECTION AND A METHOD TO PRODUCE THE ANTIGEN
Enders General preface to studies on the cultivation of poliomyelitis viruses in tissue culture
ATE354370T1 (en) INACTIVATED IMMUNOGENIC BACTERIAL WHOLE CELL COMPOSITIONS
CO4980849A1 (en) PHARMACEUTICAL COMPOSITIONS -2-HIDROXIMETIL-1,3-OXATIOLAN-5-IL) - (1H) -PIRIMIDIN-2-ONA (LA MIVUDINA), AND ITS USE IN MEDICAL THERAPY
BR0102322A (en) Virus from an infectious bursal disease virus strain, vaccine against infectious bursal disease, methods for preparing the virus, and the vaccine, and using the virus
BR0307512A (en) Methods for producing a continuous cell line, for generating and / or isolating and / or maintaining a marek disease virus strain, for producing a diagnostic antigen for a marek disease virus, for preparing a vaccine capable of inducing protection against disease in a vertebrate, and to protect a vertebrate against disease, a cell or its offspring, cell preparation, use of it, vaccine, and use of it
AR042237A1 (en) OBTAINING COCLEAR STRUCTURES, VACCINE COMPOSITIONS, ASSISTANTS AND THEIR INTERMEDIARIES
ES2085888T3 (en) VACCINE COMPOSITION.
ES2080024B1 (en) RECOMBINANT SUBUNITARY VACCINE AGAINST RABBIT VIRIC BLOOD DISEASE.